

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

138/LG/SE/MAY/2025/GBSL

May 30, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001
Scrip Code : 509079

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Symbol : GUFICBIO

Subject: Outcome of the Board of Directors Meeting held on Friday, May 30, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. Friday, May 30, 2025, *inter-alia*, considered and approved the following matters:

1. Audited (Standalone and Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31, 2025.

In terms of the provisions of Regulation 33 of the Listing Regulations, we are enclosing herewith the copy of the following as “**Annexure A**”:

- a. Audited (Standalone and Consolidated) Financial Results for the quarter and financial year ended March 31, 2025;
 - b. Independent Auditor’s Report (Standalone and Consolidated) received from the Statutory Auditors of the Company; and
 - c. A declaration of Unmodified Opinion by the Director of the Company, in respect of the Audited (Standalone and Consolidated) Financial Results of the Company for the financial year ended March 31, 2025.
2. Recommendation of Final Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the Financial Year 2024-25, subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company.

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

3. Appointment of M/s. Poddar & Co., Cost Accountants (Firm Registration No.: 101734) as the Cost Auditors of the Company for the Financial Year 2024-25 to fill the casual vacancy caused by the resignation of M/s. Kale & Associates, Cost Accountants.
4. Appointment of M/s. Manish Ghia and Associates, a peer reviewed firm of Practising Company Secretaries (Firm Unique Code: P2006MH007100) as the Secretarial Auditors of the Company for first term of 5 consecutive years commencing from the Financial Year 2025-26 to Financial Year 2029-30, subject to approval of Members of the Company at the ensuing Annual General Meeting.

The details required to be furnished for appointment of Cost Auditor and Secretarial Auditor under Regulation 30 of Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as “Annexure B”.

5. Acceptance of 512,000 equity shares out of 792,000 equity shares of Face Value of Re. 1/- each, offered by Gufic Prime Private Limited (“GPPL”), Subsidiary Company, by way of Right Issue amounting to Rs. 512,000/- and renouncement of 280,000 equity shares in favour of other existing shareholders of GPPL.

This is in line with the overall investment amount approved by the Board of Directors at its meeting held on September 25, 2024 which was intimated vide letter no. 223/LG/SE/SEP/2024/GBSL dated September 25, 2024. Post issue of the said shares, the total shareholding of the Company in GPPL would be 6,00,000/- equity shares of Face Value of Re. 1/- each.

6. Additional Investment in the equity share capital of Veira Life FZE (“VLF”), Wholly Owned Subsidiary of the Company in Dubai, UAE for an amount not exceeding Rs. 1,00,00,000/- (Rupees One Crore only). The investment will be made through permissible mode(s) as determined by the Board of Directors of VLF.
7. Additional Investment in the equity share capital of Gufic Ireland Limited (“GIL”), a Company incorporated in Ireland with the intention of making it a Wholly Owned Subsidiary of the Company, for an amount not exceeding Rs. 100,00,000/- (Rupees One Crore only). The investment will be made through permissible mode(s) as determined by the Board of Directors of GIL.

The details required to be furnished for aforementioned matters mentioned in Sr. No. 5-7 under Regulation 30 of Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are furnished in “Annexure C”.

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

The meeting of the Board of Directors commenced at 5:00 p.m. and concluded at 6:30 p.m.

Kindly take the same on your record.

Thanking You,

Yours truly,

For Gufic Biosciences Limited

Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579

Encl.: As above

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

Audited Standalone and Consolidated Statement of Financial Results for the Quarter and Year Ended March 31, 2025

1]	Sr. No.	Particulars	Standalone					Consolidated						
			Quarter Ended			Year ended		Quarter Ended			Year ended			
			31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24		
			Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited		
	1	Income												
	a	Revenue from operations	20,502.01	20,779.39	19,499.35	81,980.59	80,666.57	20,502.01	20,779.39	19,499.35	81,980.59	80,666.57		
	b	Other income	38.30	186.36	88.14	361.50	217.72	39.45	186.36	88.14	362.65	217.72		
		Total Income	20,540.31	20,965.75	19,587.49	82,342.09	80,884.29	20,541.46	20,965.75	19,587.49	82,343.24	80,884.29		
	2	Expenses												
	a	Cost of materials consumed	12,291.24	7,358.69	8,266.32	34,420.10	33,125.95	12,291.24	7,358.69	8,266.32	34,420.10	33,125.95		
	b	Purchase of stock-in-trade	1,084.89	1,554.95	1,434.11	5,541.43	5,806.09	1,084.89	1,554.95	1,434.11	5,541.43	5,806.09		
	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,409.37)	502.92	(838.91)	(2,491.42)	57.48	(4,409.37)	502.92	(838.91)	(2,491.42)	57.48		
	d	Employee benefits expense	3,557.45	3,395.77	2,960.33	12,705.06	10,962.63	3,557.45	3,395.77	2,960.33	12,705.06	10,962.63		
	e	Finance cost	839.98	490.91	364.74	2,311.16	1,535.99	839.98	490.91	364.74	2,311.16	1,535.99		
	f	Depreciation and amortisation expense	784.33	461.81	434.21	2,106.44	1,701.72	784.34	461.82	434.21	2,106.46	1,701.72		
	g	Other expenses	5,313.86	4,572.74	4,254.79	18,306.57	16,127.28	5,340.45	4,574.64	4,254.79	18,336.12	16,127.28		
		Total Expenses	19,462.38	18,337.79	16,875.58	72,899.34	69,317.14	19,488.97	18,339.70	16,875.58	72,928.90	69,317.14		
	3	Total Profit before exceptional items and tax (1-2)	1,077.93	2,627.96	2,711.91	9,442.75	11,567.15	1,052.49	2,626.05	2,711.91	9,414.34	11,567.15		
	4	Exceptional items	-	-	-	-	-	-	-	-	-	-		
	5	Total Profit Before Tax	1,077.93	2,627.96	2,711.91	9,442.75	11,567.15	1,052.49	2,626.05	2,711.91	9,414.34	11,567.15		
	6	Tax expense												
		Current tax	27.00	395.00	730.00	1,872.00	2,840.00	27.00	395.00	730.00	1,872.00	2,840.00		
		Deferred tax	251.18	300.54	(22.69)	575.13	316.54	251.20	300.54	(22.69)	575.13	316.54		
		Short/(Excess) tax provision of earlier years	2.34	-	-	2.34	(202.95)	2.34	-	-	2.34	(202.95)		
		Total Tax Expenses	280.52	695.54	707.31	2,449.47	2,953.60	280.54	695.54	707.31	2,449.47	2,953.60		
	7	Net Profit for the period from continuing operations	797.41	1,932.42	2,004.60	6,993.28	8,613.55	771.95	1,930.51	2,004.60	6,964.87	8,613.55		
		Less: Share of Profit / (Loss) transferred to Minority Interest	-	-	-	-	-	-	(0.01)	-	(0.08)	-		
	8	Total Profit for period	797.41	1,932.42	2,004.60	6,993.28	8,613.55	771.95	1,930.52	2,004.60	6,964.95	8,613.55		
	9	Other Comprehensive Income (OCI)												
		Items that will not be reclassified to Profit or Loss	(17.06)	-	(53.97)	(17.06)	(53.97)	(17.06)	-	(53.97)	(17.06)	(53.97)		
		Less: Income tax relating to items that will not be reclassified to Profit or Loss	4.29	-	13.58	4.29	13.58	4.29	-	13.58	4.29	13.58		
		Other Comprehensive Income / Loss (net of taxes)	(12.77)	-	(40.39)	(12.77)	(40.39)	(12.77)	-	(40.39)	(12.77)	(40.39)		
	10	Total Comprehensive Income	784.64	1,932.42	1,964.21	6,980.51	8,573.17	759.18	1,930.52	1,964.21	6,952.18	8,573.17		
	11	Othe Equity Reserves				59,133.51	52,253.28				59,104.90	52,253.28		
	12	Details of Equity Share Capital												
		Paid-up equity share capital	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78		
		Face value of equity share capital (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
	13	Earning per equity share												
	i	Basic earnings per share from continuing and discontinued operations	0.80	1.93	2.00	6.97	8.74	0.77	1.93	2.00	6.95	8.74		
	ii	Diluted earnings per share from continuing and discontinued operations	0.80	1.93	2.00	6.97	8.74	0.77	1.93	2.00	6.95	8.74		



Bechopn

only for identification purpose



GUFIC BIOSCIENCES LIMITED


Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069 (CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs.in Lakhs)

Audited Standalone and Consolidated Statement of Assets and Liabilities as at March 31, 2025

2]	Particulars	Standalone		Consolidated	
		As at 31-Mar-25	As at 31-Mar-24	As at 31-Mar-25	As at 31-Mar-24
		(Audited)	(Audited)	(Audited)	(Audited)
ASSETS					
Non-Current Assets					
Property, plant and equipment	47,518.09	13,828.68	47,518.09	13,828.68	
Intangible assets	634.23	561.92	634.43	561.92	
Capital work-in-progress	2,181.63	30,705.67	2,181.63	30,705.67	
Right of use assets	2,446.71	1,498.74	2,446.71	1,498.74	
Financial Assets					
i. Investments	280.95	179.47	178.43	178.43	
ii. Loans	21.58	41.44	21.58	41.44	
iii. Other financial assets	972.63	886.75	973.99	886.75	
Other non-current assets	529.17	1,504.59	529.27	1,504.59	
Total Non-Current Assets	54,584.99	49,207.26	54,484.13	49,206.22	
Current Assets					
Inventories	21,686.90	20,048.21	21,686.90	20,048.21	
Financial Assets					
i. Trade receivables	31,460.69	32,993.53	31,460.69	32,993.53	
ii. Cash and cash equivalent	1,490.88	112.64	1,572.33	113.68	
iii. Other bank balances	1,329.89	1,234.72	1,329.89	1,234.72	
iv. Loans	32.19	37.34	32.21	37.34	
Other current assets	6,220.04	5,620.46	6,213.18	5,620.46	
Current tax assets (net)	157.05	-	157.05	-	
Total Current Assets	62,377.64	60,046.90	62,452.25	60,047.94	
TOTAL ASSETS	1,16,962.63	1,09,254.16	1,16,936.38	1,09,254.16	
EQUITY AND LIABILITIES					
Equity					
Equity share capital	1,002.78	1,002.78	1,002.78	1,002.78	
Other equity	59,133.51	52,253.28	59,104.90	52,253.28	
Equity attributable to owners of the parent	60,136.29	53,256.06	60,107.68	53,256.06	
Non controlling interests	-	-	-	-	
Total Equity	60,136.29	53,256.06	60,107.68	53,256.06	
Liabilities					
Non-Current Liabilities					
Financial Liabilities					
i. Borrowings	13,049.96	15,396.31	13,049.96	15,396.31	
ii. Other Financial Liabilities	537.36	497.36	537.36	497.36	
iii. Lease liability	1,959.33	1,155.51	1,959.33	1,155.51	
Provisions	1,749.16	1,537.70	1,749.16	1,537.70	
Deferred tax liabilities (net)	777.16	206.33	777.16	206.33	
Total Non- Current Liabilities	18,072.97	18,793.21	18,072.97	18,793.21	
Current Liabilities					
Financial Liabilities					
i. Borrowings	17,987.50	16,307.14	17,987.50	16,307.14	
ii. Trade payables	-	-	-	-	
Total outstanding dues of micro enterprises and small enterprises	222.07	232.68	222.07	232.68	
Total outstanding dues of other than micro enterprises and small enterprises	15,652.88	16,394.19	15,652.88	16,394.19	
iii. Other financial liabilities	1,518.87	1,374.14	1,518.87	1,374.14	
iv. Lease liability	622.67	432.61	622.67	432.61	
Provisions	438.09	473.63	440.29	473.63	
Other current liabilities	2,311.29	1,735.97	2,311.44	1,735.97	
Current tax liabilities (net)	-	254.53	-	254.53	
Total Current Liabilities	38,753.37	37,204.89	38,755.72	37,204.89	
Total Liabilities	56,826.34	55,998.10	56,828.69	55,998.10	
TOTAL EQUITY AND LIABILITIES	1,16,962.63	1,09,254.16	1,16,936.38	1,09,254.16	



GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069 (CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs.in Lakhs)

Audited Standalone and Consolidated Statement of cash flows for the year ended March 31, 2025

3]	Particulars	Standalone		Consolidated	
		Year Ended 31-Mar-25	Year Ended 31-Mar-24	Year Ended 31-Mar-25	Year Ended 31-Mar-24
		(Audited)	(Audited)	(Audited)	(Audited)
A. Cash flows from operating activities					
	Profit for the year	6,993.28	8,613.56	6,964.87	8,613.56
	Adjustments for:				
	Income tax expense recognised in profit or loss	2,449.47	2,953.60	2,449.47	2,953.60
	Depreciation	2,106.44	1,701.72	2,106.46	1,701.72
	Dividend	-	(0.04)	-	(0.04)
	Interest income on fixed deposits with banks	(93.48)	(86.41)	(93.48)	(86.41)
	Interest income on financial assets carried at amortised cost	(54.72)	(53.52)	(54.72)	(53.52)
	Interest costs on financial liabilities measured at amortised cost	2,311.16	1,535.99	2,311.16	1,535.99
	Non current security deposits at amortised cost	57.09	58.54	57.09	58.54
	Profit on sale of fixed asset	(11.59)	-	(11.59)	-
	Loss on sale of fixed asset	-	229.95	-	229.95
	Sundry credit balances written back	53.99	28.34	53.99	28.34
	Operating profit before movements in the working capital	13,811.64	14,981.73	13,783.25	14,981.73
	Movements in working capital:				
	(Increase)/decrease in trade and other receivables	731.10	(15,324.19)	735.48	(15,324.19)
	(Increase)/decrease in inventories	(1,638.69)	(1,702.46)	(1,638.69)	(1,702.46)
	Increase/ (Decrease) in trade and other payables	1,654.90	4,003.32	1,657.95	4,003.32
		747.31	(13,023.33)	754.73	(13,023.33)
	Cash generated from / (used in) operations	14,558.95	1,958.40	14,537.98	1,958.40
	Income taxes paid	(2,281.18)	(2,704.36)	(2,281.18)	(2,704.36)
	Net cash generated from / (used in) operating activities (A)	12,277.77	(745.96)	12,256.80	(745.96)
B. Cash flows from investing activities					
	Purchase of property, plant and equipments including capital advances	(7,552.34)	(11,269.46)	(7,552.55)	(11,269.46)
	Purchase of Investment in Equity Shares of Subsidiary	(101.48)	(101.04)	-	(100.00)
	Sale of property, plant and equipments	476.69	456.62	476.69	456.62
	Other dividend received	-	0.29	-	0.29
	Minority in new acquisition	-	-	0.12	-
	Balance in earmarked accounts	(95.17)	573.51	(95.17)	573.51
	Interest income on fixed deposits with banks	93.18	100.14	93.18	100.14
	Net cash used in investing activities (B)	(7,179.12)	(10,239.94)	(7,077.73)	(10,238.90)
C. Cash flows from financing activities					
	Proceeds from issuance of shares	-	9,999.00	-	9,999.00
	Proceeds / (Repayment) from current borrowings	(2,354.68)	4,234.36	(2,354.68)	4,234.36
	Proceeds / (Repayment) from non current borrowings	1,680.36	(3,683.66)	1,680.36	(3,683.66)
	Processing fees paid	-	(56.00)	-	(56.00)
	Payment on lease liabilities	(642.98)	(690.45)	(642.98)	(690.45)
	Payment for Interest lease liability	(215.02)	(206.24)	(215.02)	(206.24)
	Dividends paid on equity shares	(100.28)	(96.94)	(100.28)	(96.94)
	Interest paid	(2,087.81)	(1,261.72)	(2,087.81)	(1,261.72)
	Net cash generated from financing activities (C)	(3,720.41)	8,238.35	(3,720.41)	8,238.35
	Net increase in cash and cash equivalents (A + B + C)	1,378.24	(2,747.55)	1,458.65	(2,746.51)
	Cash and cash equivalents at the beginning of the year	112.64	2,860.19	113.68	2,860.19
	Cash and cash equivalents at the end of the period	1,490.88	112.64	1,572.33	113.68



4] Notes:

1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
2. The above results for the quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 30, 2025. The Statutory Auditors have carried out audit of the results for quarter and year ended March 31, 2025.
3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
4. The Board of Directors at its meeting held on May 30, 2025 has recommended a final dividend of Re. 0.10/- per equity share i.e. @ 10% on the face value of Re. 1/- each, for the financial year 2024-25, subject to the approval of the shareholders at the ensuing Annual General Meeting.
5. The Company has incorporated Gufic UK Limited ("GUL") in United Kingdom on March 15, 2022, Gufic Ireland Limited ("GIL") in Ireland on March 02, 2023, Veira Life FZE ("VLF") in Dubai, UAE on March 25, 2024 and Gufic Prime Private Limited ("GPPL") in India on November 18, 2023, with the intention of making GUL, GIL and VLF its Wholly Owned Subsidiaries and GPPL as its Subsidiary Company. As of March 31, 2025, neither investment have been made in GIL nor they have begun its business operations. Consequently, there was no need to consolidate the accounts of GIL with the Company. However, the Company has invested in GUL on September 13, 2023, GPPL on April 25, 2024 and VLF on January 13, 2025 by subscribing to its shares. Consequently, the consolidated financial results for the quarter and financial year ended March 31, 2025, have been prepared by the Company considering the financials of GUL, GPPL and VLF.
6. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share.
7. The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2024 and December 31, 2023 respectively, which were subjected to limited review.
8. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED


PRANAV J. CHOKSI
CEO & WHOLE TIME DIRECTOR
DIN : 00001731

PLACE : MUMBAI
DATE : 30/05/2025





Independent Auditor's Report on the Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Gufic Biosciences Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of **Gufic Biosciences Limited** (hereinafter referred to as the "Company") for the quarter and year ended 31 March 2025 ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid statement:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended 31 March 2025.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion.

Managements and Board of Directors' Responsibilities for the Standalone Financial Results

These standalone financial results have been prepared on the basis of the standalone financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of





adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone financial results include the results for the quarter ended 31 March 2025, which are balancing figures between the audited figures in respect of the full financial year and published unaudited figures for the nine months ended 31 December 2024 which were subject to limited review by us.



Place: Mumbai
Dated: 30/05/2025

UDIN: 25C39486BMK5JQ7649

For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)

Deepesh Mittal
Partner

Membership No. 539486



**Independent Auditor's Report on the Audited Consolidated Financial Results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements)
Regulations, 2015, as amended**

To
The Board of Directors
Gufic Biosciences Limited

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying consolidated financial results of **Gufic Biosciences Limited** (hereinafter referred to as the "Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the quarter and year ended 31 March 2025 ("the statement" or "consolidated financial results"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid statement:

- a. includes the annual financial results of the subsidiaries named;

S no	Name of the Company	Relationship
1	Gufic Prime Private Limited	Subsidiary
2	Gufic UK Limited	Foreign Subsidiary
3	Veira Life FZE	Foreign Subsidiary

- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended 31 March 2025.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion.

Managements and Board of Directors' Responsibilities for the Consolidated Financial Results

These consolidated financial results have been prepared on the basis of the consolidated financial statements.





The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the entities included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each entity and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Management and the Board of Directors of the entities included in the Group are responsible for assessing the ability of each entity to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the entities included in the Group are responsible for overseeing the financial reporting process of each entity.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of consolidated financial statements on whether the company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.





- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors of the Holding Company.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the consolidated financial results. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

1. The financial results of foreign subsidiaries have been prepared in accordance with the accounting principles generally accepted in their respective countries. The management of the Company has converted the financial results of such foreign subsidiaries from their local accounting principles to Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013. Our conclusion, insofar as it relates to the balances and affairs of these subsidiaries located outside India, is based on the financial results/statements as certified by the management and the conversion adjustments prepared by them. Our conclusion is not modified in respect of this matter.
2. The consolidated financial results include the results for the quarter ended 31 March 2025, which are balancing figures between the audited figures in respect of the full financial year and published unaudited figures for the nine months ended 31 December 2024 which were subject to limited review by us.



For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)



MITTAL AGARWAL & COMPANY
CHARTERED ACCOUNTANTS

Place: Mumbai
Dated: 30/05/2025
UDIN: 25539486BMRSJRA58



Deepesh Mittal

Deepesh Mittal
Partner
Membership No. 539486

29401

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax : (+91-22) 6726 1067, Email : info@guficbio.com, Website : www.gufic.com

137/LG/SE/MAY/2025/GBSL

May 30, 2025

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001
Scrip Code: 509079

To,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Scrip Symbol: GUFICBIO

Sub.: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016

Dear Sir/ Madam,

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, I, Pranav Choksi (DIN: 00001731), Chief Executive Officer & Whole Time Director, hereby declare that M/s. Mittal Agarwal & Co., Chartered Accountants (FRN - 131025W), Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2025.

Kindly take the same on record.

Thanking You,

Yours faithfully,

For Gufic Biosciences Limited



Pranav J. Choksi
Chief Executive Officer & Whole Time Director
(DIN: 00001731)

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

Annexure B

Particulars	Appointment of Cost Auditor (Item No. 3)	Appointment of Secretarial Auditor (Item No.4)
Reason for change	Appointment to fill the casual vacancy caused by the resignation of M/s. Kale & Associates, Cost Accountants.	Appointment
Date of Appointment	30.05.2025	30.05.2025
Term of Appointment	Appointed as a Cost Auditor of the Company for the Financial Year 2024-25.	Appointed as a Secretarial Auditor of the Company for the first term of five consecutive years commencing from Financial Year 2025-26 to 2029-30 to issue Secretarial Audit Report and Annual Secretarial Compliance Report for the said period.
Brief Profile	<p>Name of the Firm: M/s. Poddar & Co., Cost Accountants</p> <p>Brief Profile: M/s. Poddar & Co. is a specialized Cost Accounting firm led by its Proprietor, Mr. Sandeep Poddar, a qualified Cost Accountant with 15 years of professional experience in Cost and Management Accounting across diverse industries and companies of repute.</p> <p>The Firm offers a comprehensive suite of costing services, including Statutory Cost Audits, Certifications, setting up costing systems, cost consultancy, and developing costing-based turnaround strategies. In</p>	<p>Name of the Firm: M/s. Manish Ghia & Associates</p> <p>Brief Profile: M/s. Manish Ghia and Associates, Practicing Company Secretaries (MGA) is a well-known peer reviewed firm of Company Secretaries having more than 2 decades of expertise in providing professional services in the space of Assurance & Certification, Corporate Governance and Compliances. Over the years, MGA has built a strong reputation for secretarial audits and due diligence with its meticulous processes and skilled resources. MGA in its offerings serves a diverse range of industries including financial services, Gaming & Tech, Pharmaceuticals, health and diagnostics, infrastructure etc. The firm also offers advisory and</p>

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

	<p>addition to core costing work, M/s. Poddar & Co. also undertakes Internal Audits and Stock & Assets Verification assignments.</p> <p>The firm has successfully conducted Cost Audits for clients in sectors such as Pharmaceuticals, Mineral Fuels, Chemicals, Road and Infrastructure, Real Estate, Insecticides, Home Appliances, Telecommunications, and various Other Machinery industries, etc.</p>	<p>compliance support under various corporate laws including Company Law, SEBI Regulations, FEMA and RBI directions to ensure seamless regulatory adherence.</p>
<p>Details of relationships between directors (in case of appointment of a director)</p>	<p>Not Applicable</p>	<p>Not Applicable</p>

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)
Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

Annexure-C

Sr. No.	Particulars	Details (Item No. 5)	Details (Item No. 6)	Details (Item No. 7)
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Name of the Company: Gufic Prime Private Limited (“GPPL/ Subsidiary Company”).</p> <p>Authorized Capital: Rs. 15,00,000/- (Rupees Fifteen Lakhs only)</p> <p>Paid up Capital: Rs. 100,000/- (Rupees One Lakhs only)</p> <p>Size/Turnover: Nil, as GPPL is yet to commence its business operations.</p>	<p>Name of the Company: Veira Life FZE (“VLF/ Wholly Owned Subsidiary Company”).</p> <p>Authorized Capital: AED 200,000/- (AED Two Lakhs only)</p> <p>Paid up Capital: AED 200,000/- (AED Two Lakhs only)</p> <p>Size/Turnover: Nil, as VLF is yet to commence its business operations.</p>	<p>Name of the Company: Gufic Ireland Limited (“GIL”).</p> <p>Issued Capital: 1000 unpaid ordinary shares of 1 Euro each.</p> <p>Size/Turnover: Nil, as GIL is yet to commence its business operations.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and	<p>GPPL, being a Subsidiary is a related party of the Company. The transaction falls within the ambit of related party transactions and is at arms’ length.</p> <p>Save and except what is mentioned above, the promoter / promoter group are not interested in the said transaction.</p>	<p>VLF, being a Wholly Owned Subsidiary is a related party of the Company. The transaction falls within the ambit of related party transactions and is at arms’ length.</p> <p>Save and except what is mentioned above, the promoter / promoter</p>	<p>Post completion of the Company’s initial subscription in the ordinary shares of GIL, it will become a Related Party of the Company and the said transaction will fall within the ambit of related party transactions and will be at arms’ length.</p>

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

	whether the same is done at "arm's length"		group are not interested in the said transaction.	Save and except what is mentioned above, the promoter / promoter group are not interested in the said transaction.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals	Pharmaceuticals	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	GPPL is engaged in the business of marketing, distribution and sale of pharmaceutical products. The business of the subsidiary is in line with the main line business of the Company.	VLF is engaged in the business of marketing, distribution and sale of pharmaceutical products. The business of the subsidiary is in line with the main line business of the Company.	GIL is engaged in the business of marketing, distribution and sale of pharmaceutical products. The business of the GIL is in line with the main line business of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable	Not Applicable	Not Applicable
6.	Indicative time period for completion of the acquisition	Within three to six months	Within twelve months	Within twelve months
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration	Cash Consideration	Cash Consideration
8.	Cost of acquisition or the price at which the shares are acquired;	Rs. 512,000/- (Rupees Five Lakhs Twelve Thousand only) (512,000 equity shares of	Not exceeding Rs. 100,00,000/- (Rupees One Crore only).	Not exceeding Rs. 100,00,000/- (Rupees One Crore only).

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

		Face Value of Re.1/- by way of Right Issue)	Details will be updated once the transaction is complete.	Details will be updated once the transaction is complete.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Details will be updated once the transaction is complete.	Details will be updated once the transaction is complete.	Details will be updated once the transaction is complete.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>GPPL was incorporated under the Companies Act, 2013 on November 18, 2023 as a subsidiary of the Company.</p> <p>GPPL is engaged in the business of marketing, distribution and sale of pharmaceutical products.</p> <p>GPPL is yet to commence its business operations.</p> <p>Country of presence of GPPL: India</p>	<p>VLF was incorporated on March 25, 2024 as a Wholly Owned Subsidiary of the Company.</p> <p>VLF is engaged in the business of marketing, distribution and sale of pharmaceutical products.</p> <p>VLF is yet to commence its business operations.</p> <p>Country of presence of VLF: Dubai, UAE</p>	<p>GIL was incorporated on March 2, 2023 with the intention of making it a Wholly Owned Subsidiary of the Company.</p> <p>GIL is engaged in the business of marketing, distribution and sale of pharmaceutical products.</p> <p>GIL is yet to commence its business operations.</p> <p>Country of presence of GIL: Ireland</p>

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka